From: Prognostic and clinicopathologic significance of circZFR in multiple human cancers
Subgroups | No. of studies | No. of patients | HR (95% CI) | Model | Heterogeneity | |
---|---|---|---|---|---|---|
I2 (%) | p value | |||||
1 Sample size | ||||||
 1.1 ≥ 60 | 7 | 499 | 1.90 (1.47, 2.45) | Fixed | 31.6 | 0.187 |
 1.2< 60 | 4 | 190 | 2.73 (1.90, 3.91) | Fixed | 0.00 | 0.760 |
2 Cancer type | ||||||
 2.1 BlC | 3 | 219 | 2.41 (1.59, 3.66) | Random | 0.00 | 0.895 |
 2.2 BrC | 2 | 135 | 1.43 (0.54, 3.79) | Random | 78.9 | 0.030 |
 2.3 HCC | 3 | 190 | 2.38 (1.66, 3.40) | Random | 0.00 | 0.644 |
 2.4 Others | 3 | 145 | 2.65 (1.63, 4.29) | Random | 0.00 | 0.608 |
3 Follow-up | ||||||
 3.1 ≥ 60 | 10 | 624 | 2.44 (1.95, 3.05) | Fixed | 0.00 | 0.987 |
 3.2< 60 | 1 | 65 | 1.38 (0.57, 3.33) | Fixed | – | – |
4 Cut-off value | ||||||
 4.1 Mean | 1 | 80 | 2.05 (1.01, 4.16) | Fixed | – | – |
 4.2 Median | 5 | 344 | 2.38 (1.77, 3.20) | Fixed | 0.00 | 0.826 |
 4.3 N/A | 5 | 265 | 2.39 (1.73, 3.29) | Fixed | 0.00 | 0.848 |